Tag: Multiple Sclerosis
AAN: Oral BTK Inhibitor Superior to Placebo in Multiple Sclerosis
Fewer enhancing lesions seen in weeks 12 to 24 for 75 mg evobrutinib once daily versus placebo
Significant Number of Referred Patients Misdiagnosed With MS
At MS referral centers, almost one in five new patients have been incorrectly diagnosed with the disease
African-Americans With ALS Survive Longer Than Caucasians
Difference no longer significant when outcome is death or tracheostomy and invasive ventilation
Cortical Lesions in Multiple Sclerosis Tracked With 7.0-T MRI
Development of cortical lesions surpassed that of white matter lesions, linked to neurologic disability
Beta Interferon Tied to Lower Mortality in Relapsing-Onset MS
Increased survival seen with more than three years of beta interferon exposure but not lower exposure
Minerals Not Linked to Multiple Sclerosis Risk in Women
Associations null when women with highest versus lowest intake in quintiles, deciles compared
FDA Approves Mavenclad for Treating Multiple Sclerosis
Treatment indicated for patients with relapsing-remitting, active secondary progressive MS
FDA Approves Mayzent for Relapsing Multiple Sclerosis
Oral medication must be dispensed with important information about the drug's uses and risks
Older Age at Puberty Linked to Lower Odds of Multiple Sclerosis
After adjustment for effects on adult BMI, correlation between age at puberty with MS was attenuated
Neighborhood-Level Socioeconomics Tied to MS Disability Progression
Lower socioeconomic status associated with higher risk for multiple sclerosis disability progression
